Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

Research led by the Department of General and Visceral Surgery, Faculty of Medicine, University of Freiburg, Germany has ...

Exelixis stock shines with 36% CABOMETYX sales growth, promising zanzalintinib market expansions, and raised 2025 guidance.

Each year, it is estimated more than 40,000 people will be diagnosed with liver cancer – and those numbers are increasing.

Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with ...

Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at ...

The cancer charity Planets is leading the campaign for the treatment, known as selective internal radiation therapy, to be made available on the NHS.

The combination of cabozantinib and atezolizumab appeared more effective than switching ARPI therapy in patients with mCRPC and extrapelvic soft-tissue metastases.

Hepatitis B virus (HBV) infection is known to be associated with the risk of hepatocellular carcinoma (HCC), but how and why ...